REVIEW ARTICLE
Year : 2022 | Volume
: 9 | Issue : 1 | Page : 9-
Role of TGF-β Signaling in Coronavirus Disease 2019
Junzhe Chen1, Wenjing Wu3, Wenbiao Wang2, Ying Tang3, Hui- Yao Lan5
1 Department of Nephrology, The Third Affiliated hospital, Southern Medical University, Guangzhou; Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, China
2 Medical Research Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
3 Department of Nephrology, The Third Affiliated hospital, Southern Medical University, Guangzhou, China
Correspondence Address:
Hui- Yao Lan
Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong
China
Coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations involving the respiratory, cardiovascular, renal, neuropsychiatric, gastrointestinal, and dermatological systems. Some patients with COVID-19 experience acute infection and post-COVID-19 syndrome. There is increasing evidence that TGF-β signaling plays an important role in the pathogenesis of both acute and chronic COVID-19 infection. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein was reported to interact with Smad3, a key downstream mediator of TGF-β signaling, thereby promoting TGF-β1/Smad3 signaling and causing cell death during the acute phase of COVID-19 infection. Because activation of TGF-β/Smad3 signaling has an essential role in multiple organ fibrosis, it is possible that overreactive TGF-β/Smad3 signaling may cause tissue fibrosis in the lung, heart, and kidney after SARS-CoV-2 infection. Thus, not only administration of antiviral drugs and traditional Chinese medicines, but also targeting of TGF-β signaling components, particularly Smad3, with various therapeutic strategies involving OT-101, pirfenidone, and specific Smad3 inhibitors, such as SIS3, may provide novel and specific therapies for COVID-19 patients.
How to cite this article:
Chen J, Wu W, Wang W, Tang Y, Lan HY. Role of TGF-β Signaling in Coronavirus Disease 2019.Integr Med Nephrol Androl 2022;9:9-9
|
How to cite this URL:
Chen J, Wu W, Wang W, Tang Y, Lan HY. Role of TGF-β Signaling in Coronavirus Disease 2019. Integr Med Nephrol Androl [serial online] 2022 [cited 2023 Mar 26 ];9:9-9
Available from: https://journal-imna.com//article.asp?issn=2773-0387;year=2022;volume=9;issue=1;spage=9;epage=9;aulast=Chen;type=0 |
|
